Shanghai Pharmaceuticals Holding Co., Ltd (HKG:2607)
12.72
-0.02 (-0.16%)
Jul 29, 2025, 9:45 AM HKT
HKG:2607 Revenue
Shanghai Pharmaceuticals Holding had revenue of 70.76B CNY in the quarter ending March 31, 2025, with 0.87% growth. This brings the company's revenue in the last twelve months to 275.86B, up 4.41% year-over-year. In the year 2024, Shanghai Pharmaceuticals Holding had annual revenue of 275.25B with 5.75% growth.
Revenue (ttm)
275.86B CNY
Revenue Growth
+4.41%
P/S Ratio
0.24
Revenue / Employee
5.58M CNY
Employees
49,402
Market Cap
69.70B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 275.25B | 14.96B | 5.75% |
Dec 31, 2023 | 260.30B | 28.31B | 12.21% |
Dec 31, 2022 | 231.98B | 16.16B | 7.49% |
Dec 31, 2021 | 215.82B | 23.92B | 12.46% |
Dec 31, 2020 | 191.91B | 5.34B | 2.86% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
BeOne Medicines | 32.49B |
Hansoh Pharmaceutical Group Company | 13.05B |
JD Health International | 61.89B |
Innovent Biologics | 10.03B |
Akeso | 2.26B |
WuXi Biologics | 19.87B |
Sino Biopharmaceutical | 30.72B |
CSPC Pharmaceutical Group | 28.99B |
Shanghai Pharmaceuticals Holding News
- 7 months ago - Chinese Cancer Drug Developer Hutchmed Sharpens R&D Focus, Divests Non-Core JV For Over $600 Million - Benzinga
- 7 months ago - HUTCHMED to divest 45% stake in JV with Shanghai Pharma - Seeking Alpha